| Ryan Ray Morgan, CRNA | |
|
1000 Hospital Dr, Mcpherson, KS 67460-2326 | |
| (620) 241-2250 | |
| (620) 241-6066 |
| Full Name | Ryan Ray Morgan |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 19 Years |
| Location | 1000 Hospital Dr, Mcpherson, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326007485 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 55475 (Kansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ad Astra Anesthesia, Llc | 7810898608 | 6 |
| Special Anesthesia Services Pa | 4082618467 | 3 |
News Archive
Six of New York State's largest public and private health plans are receiving valuable leads for their Medicaid managed care, Child Health Plus, and Family Health Plus programs, thanks to a new Web site that allows New Yorkers to quickly screen for public health insurance program eligibility.
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Scientists have known that genetic mutations leading to the production of a defective protein called GFAP cause Alexander disease (AxD), a debilitating neurodegenerative condition that can present during infancy, adolescence, or adulthood.
Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable.
For baseball players with superior labral tears, conservative shoulder treatment may offer a better chance of returning to play than surgery, say US researchers.
› Verified 3 days ago
| Entity Name | Ad Astra Anesthesia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316918816 PECOS PAC ID: 7810898608 Enrollment ID: O20040115000467 |
News Archive
Six of New York State's largest public and private health plans are receiving valuable leads for their Medicaid managed care, Child Health Plus, and Family Health Plus programs, thanks to a new Web site that allows New Yorkers to quickly screen for public health insurance program eligibility.
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Scientists have known that genetic mutations leading to the production of a defective protein called GFAP cause Alexander disease (AxD), a debilitating neurodegenerative condition that can present during infancy, adolescence, or adulthood.
Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable.
For baseball players with superior labral tears, conservative shoulder treatment may offer a better chance of returning to play than surgery, say US researchers.
› Verified 3 days ago
| Entity Name | Special Anesthesia Services Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528035714 PECOS PAC ID: 4082618467 Enrollment ID: O20060828000464 |
News Archive
Six of New York State's largest public and private health plans are receiving valuable leads for their Medicaid managed care, Child Health Plus, and Family Health Plus programs, thanks to a new Web site that allows New Yorkers to quickly screen for public health insurance program eligibility.
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Scientists have known that genetic mutations leading to the production of a defective protein called GFAP cause Alexander disease (AxD), a debilitating neurodegenerative condition that can present during infancy, adolescence, or adulthood.
Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable.
For baseball players with superior labral tears, conservative shoulder treatment may offer a better chance of returning to play than surgery, say US researchers.
› Verified 3 days ago
| Entity Name | Kansas Spine Anesthesia Corporation Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720345911 PECOS PAC ID: 1153586821 Enrollment ID: O20120702000174 |
News Archive
Six of New York State's largest public and private health plans are receiving valuable leads for their Medicaid managed care, Child Health Plus, and Family Health Plus programs, thanks to a new Web site that allows New Yorkers to quickly screen for public health insurance program eligibility.
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Scientists have known that genetic mutations leading to the production of a defective protein called GFAP cause Alexander disease (AxD), a debilitating neurodegenerative condition that can present during infancy, adolescence, or adulthood.
Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable.
For baseball players with superior labral tears, conservative shoulder treatment may offer a better chance of returning to play than surgery, say US researchers.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Ray Morgan, CRNA 405 Evergreen Ct, Mcpherson, KS 67460-2303 Ph: (620) 245-0794 | Ryan Ray Morgan, CRNA 1000 Hospital Dr, Mcpherson, KS 67460-2326 Ph: (620) 241-2250 |
News Archive
Six of New York State's largest public and private health plans are receiving valuable leads for their Medicaid managed care, Child Health Plus, and Family Health Plus programs, thanks to a new Web site that allows New Yorkers to quickly screen for public health insurance program eligibility.
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Scientists have known that genetic mutations leading to the production of a defective protein called GFAP cause Alexander disease (AxD), a debilitating neurodegenerative condition that can present during infancy, adolescence, or adulthood.
Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable.
For baseball players with superior labral tears, conservative shoulder treatment may offer a better chance of returning to play than surgery, say US researchers.
› Verified 3 days ago
Ryan Douglas Kuhn, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1000 Hospital Dr, Mcpherson, KS 67460 Phone: 620-241-2250 | |
Marc Romney Williamson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1000 Hospital Dr, Mcpherson, KS 67460 Phone: 620-241-2250 | |
Michael T Nason, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1000 Hospital Dr, Mcpherson, KS 67460 Phone: 620-241-2250 |